PolyPid to Participate in The Citizens Life Sciences Conference

Group 1 - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through innovative drug delivery systems [2] - The company utilizes its proprietary PLEX technology for controlled, prolonged-release therapeutics, allowing for precise drug delivery over extended periods [2] - PolyPid's lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials aimed at preventing abdominal colorectal surgical site infections [2] Group 2 - The company is also in preclinical stages testing OncoPLEX for the treatment of solid tumors, starting with glioblastoma [2] - PolyPid management will participate in a fireside chat at The Citizens Life Sciences Conference in New York on May 7, 2025 [1] - Investors interested in meeting with PolyPid during the conference can contact their Citizens JMP representative [1]